Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY4256984 in Sporadic Amyotrophic Lateral Sclerosis (Long-Term Extension)
NCT07571174Phase 1Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- May 2026
- Primary completion
- Jun 2029
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label, single-arm trial of LY4256984 in amyotrophic lateral sclerosis (ALS), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration at 96 weeks. Started May 2026; status: recruiting.
02
Drugs
LY4256984
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT07571174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07571174.